134 related articles for article (PubMed ID: 20001245)
1. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?
Mikhaeel NG
Leuk Lymphoma; 2009 Dec; 50(12):1931-6. PubMed ID: 20001245
[TBL] [Abstract][Full Text] [Related]
2. Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma.
Huntington SF; Nasta SD; Schuster SJ; Doshi JA; Svoboda J
Leuk Lymphoma; 2015; 56(9):2579-84. PubMed ID: 25629993
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
4. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
5. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
6. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand?
Meignan M; Itti E; Gallamini A; Haioun C
Leuk Lymphoma; 2009 Nov; 50(11):1753-6. PubMed ID: 19863178
[TBL] [Abstract][Full Text] [Related]
7. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
8. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.
Lanic H; Mareschal S; Mechken F; Picquenot JM; Cornic M; Maingonnat C; Bertrand P; Clatot F; Bohers E; Stamatoullas A; Leprêtre S; Rainville V; Ruminy P; Bastard C; Tilly H; Becker S; Vera P; Jardin F
Leuk Lymphoma; 2012 Jan; 53(1):34-42. PubMed ID: 21806349
[TBL] [Abstract][Full Text] [Related]
9. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
[TBL] [Abstract][Full Text] [Related]
10. Role of early PET in the management of diffuse large B-cell lymphoma.
Michallet AS; Trotman J; Tychyj-Pinel C
Curr Opin Oncol; 2010 Sep; 22(5):414-8. PubMed ID: 20683268
[TBL] [Abstract][Full Text] [Related]
11. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
[TBL] [Abstract][Full Text] [Related]
12. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
14. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
[TBL] [Abstract][Full Text] [Related]
15. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
[TBL] [Abstract][Full Text] [Related]
17. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
18. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
